TAIPEI, Taiwan May 16, 2024 – ImmunAdd, a privately held company developing a fully synthetic saponin-based small molecule, attended to WVC Washington during 4/2~4/4. ImmunAdd is a group of scientists with extensive knowledge of medical chemistry, drug formulation, drug regulations, biological animal evaluation, and clinical trials, and is working on developing drugs for infectious disease, […]
TAIPEI, Taiwan May 16, 2024 – ImmunAdd, a privately held company developing a fully synthetic saponin-based small molecule, attends BIO International Convention during 6/3~6/6 and will be in Taiwan Pavilon (Booth: 1917). ImmunAdd developed a synthetic saponin IA-05 which can be synthesized in large scale and manufactured in GMP facility. IA-05 is formulated in aqueous […]
TAIPEI, Taiwan May 16, 2024 – ImmunAdd, a privately held company developing a fully synthetic saponin-based small molecule, proudly announced that our funder and CEO, Dr. Pi-Hui Liang, awarded “Outstanding Research Award”. Dr. Pi-Hui Liang leads her team, leaning on their erudite knowledge in medical chemistry, drug formulation, and regulations, to work on developing therapies […]